Landscape

Genetic Hearing Loss

Genetic Hearing Loss has 18 tracked records across 9 named organizations, including 4 strong-evidence records and 5 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.

All Programs Therapeutics Devices

Open filtered programs

Pipeline Records

strong evidence + caveats + candidates

Strong Evidence

14 checked records with caveats

Active Programs

currently active

Marketed / Approved

commercial or approved

Organizations

companies, sponsors, and institutions

Competitive Density

30/100

organization breadth + program volume

Pipeline Velocity

21/100

active and late-stage share

Evidence Coverage

22/100

share strong evidence

Completion Signal

11/100

late-stage, approved, or marketed

Attrition Rate

17/100

share discontinued

Concentration

28/100

top-organization share

Programs by Stage

Preclinical6 · 33%

Early Phase 11 · 6%

Phase 1/22 · 11%

Phase 24 · 22%

Phase 2/31 · 6%

Interventional/NA3 · 17%

Approved1 · 6%

Trial / Program Status

Active5 · 28%

Approved1 · 6%

Completed1 · 6%

Discontinued3 · 17%

Unknown8 · 44%

Modality Breakdown

Gene Therapy12 · 67%

Small Molecule5 · 28%

RNA Therapy1 · 6%

Program Types

Therapeutic18 · 100%

Top Organizations

Institution-led study5 · 28%

Eli Lilly and Company3 · 17%

Regeneron Pharmaceuticals3 · 17%

Sensorion2 · 11%

HuidaGene Therapeutics Co., Ltd.1 · 6%

Khondrion BV1 · 6%

Otonomy1 · 6%

OtoVia Therapeutics1 · 6%

Population Tags

genetic18 · 100%

pediatric14 · 78%

congenital10 · 56%

pre-lingual8 · 44%

adult6 · 33%

bilateral4 · 22%

otof-dfnb94 · 22%

profound4 · 22%

syndromic3 · 17%

otof2 · 11%

Strong-Evidence Programs

4 records

Otarmeni by RegeneronStrong evidence

Company: Regeneron Pharmaceuticals · Approved · Approved

Gene TherapyApprovedApproved99% confidence

AK-OTOF by Eli Lilly and AkouosStrong evidence

Company: Eli Lilly and Company · Phase 2 · Active

Gene TherapyPhase 2Active95% confidence

SENS-501 by SensorionStrong evidence

Company: Sensorion · Phase 1/2 · Active

Gene TherapyPhase 1/2Active94% confidence

GJB2-GT by SensorionStrong evidence

Company: Sensorion · Preclinical · Active

Gene TherapyPreclinicalActive88% confidence

Checked Records With Caveats

14 records

OTO-825 by Otonomy

Company: Otonomy · Preclinical · Discontinued

Gene TherapyPreclinicalDiscontinued87% confidence

EHT102 by EuHearingStatus caveat

Company: Shanghai EuHearing Therapeutics Co., Ltd · Phase 1/2 · Active

Gene TherapyPhase 1/2Active90% confidence

OTOV101N + OTOV101C by OtoVia TherapeuticsStatus caveat

Company: OtoVia Therapeutics · Interventional/NA · Unknown

Gene TherapyInterventional/NAUnknown86% confidence

HG205 RNA base-editing therapy by HuidaGeneStatus caveat

Company: HuidaGene Therapeutics Co., Ltd. · Early Phase 1 · Discontinued

RNA TherapyEarly Phase 1Discontinued88% confidence

KH176 by Khondrion for m.3243A>G mitochondrial diseaseStatus caveat

Company: Khondrion BV · Phase 2 · Completed

Small MoleculePhase 2Completed86% confidence

Colorado SLOS Cholesterol and Antioxidant StudyStatus caveat

Sponsor / Institution: Institution-led study · Phase 2 · Unknown

Small MoleculePhase 2Unknown84% confidence

Fudan EH002 OTOF gene therapy studyStatus caveat

Sponsor / Institution: Institution-led study · Interventional/NA · Active

Gene TherapyInterventional/NAActive84% confidence

Hadassah Wolfram Syndrome Type 2 Combination Therapy StudyStatus caveat

Sponsor / Institution: Institution-led study · Phase 2 · Unknown

Small MoleculePhase 2Unknown84% confidence

GJB2 hearing loss gene therapy by Eli LillyStatus caveat

Company: Eli Lilly and Company · Preclinical · Unknown

Gene TherapyPreclinicalUnknown82% confidence

National Taiwan University Proton Pump Inhibitor SLC26A4 Hearing-Loss StudyStatus caveat

Sponsor / Institution: Institution-led study · Phase 2/3 · Unknown

Small MoleculePhase 2/3Unknown82% confidence

AK-CLRN1 by Eli LillyStatus caveat

Company: Eli Lilly and Company · Preclinical · Unknown

Gene TherapyPreclinicalUnknown80% confidence

AAV.103 by RegeneronStatus caveat

Company: Regeneron Pharmaceuticals · Preclinical · Unknown

Gene TherapyPreclinicalUnknown78% confidence

AAV.104 by RegeneronStatus caveat

Company: Regeneron Pharmaceuticals · Preclinical · Unknown

Gene TherapyPreclinicalUnknown78% confidence

Exenatide Wolfram Syndrome StudyStatus caveat

Sponsor / Institution: Institution-led study · Interventional/NA · Discontinued

Small MoleculeInterventional/NADiscontinued70% confidence